Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 2, 2017, Pages 222-227

  Gulati, Roman ^a   Cheng, Heather H ^a   Lange, Paul H ^b   Nelson, Peter S ^a   Etzioni, Ruth ^a  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRAP PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; DNA; PROSTATE SPECIFIC ANTIGEN; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SPECIFIC SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL OUTCOME; COMPUTER SIMULATION; DIAGNOSTIC ERROR; GENE FREQUENCY; GENETIC SCREENING; GERMLINE MUTATION; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK BENEFIT ANALYSIS; TUMOR BIOPSY; BIOPSY; DNA MUTATIONAL ANALYSIS; EARLY CANCER DIAGNOSIS; GENETICS; MASS SCREENING; METABOLISM; MORBIDITY; MUTATION; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATE TUMOR; RISK FACTOR; SURVIVAL RATE; TRENDS; UNITED STATES;

ADULT; AGED; BIOPSY; BRCA2 PROTEIN; COMPUTER SIMULATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EARLY DETECTION OF CANCER; GENETIC TESTING; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MORBIDITY; MUTATION; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; UBIQUITIN-PROTEIN LIGASES; UNITED STATES;

EID: 85013665683     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0434     Document Type: Article

References (34)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35.
3. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94: 981-90.
4. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-34.
5. Canadian Task Force on Preventive Health Care, Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014;186:1225-34.
6. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010;60:70-98.
7. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013; 190:419-26.
8. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158:761-9.
9. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993;150:797-802.
10. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 2014; 66:489-99.
11. Chornokur G, Dalton K, Borysova ME, Kumar NB. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 2011;71:985-97.
12. Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013;31:1748-57.
13. Castro E, Goh C, Leongamornlert D, Saunders E, Tymrakiewicz M, Dadaev T, et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur Urol 2015;68:186-93.
14. Bratt O, Loman N. Clinical management of prostate cancer in men with BRCA mutations. Eur Urol 2015;68:194-5.
15. Gulati R, Inoue L, Katcher J, Hazelton W, Etzioni R. Calibrating disease progression models using population data: A critical precursor to policy development in cancer control. Biostatistics 2010;11: 707-19.
16. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: Model estimates of potential benefits and harms. Ann Intern Med 2013; 158:145-53.
17. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
18. Mariotto A, Etzioni R, KrapchoM, Feuer EJ.Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer 2007; 109:1877-86.
19. Andriole GL. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104: 125-32.
20. GulatiR, Tsodikov A,Wever EM, Mariotto AB, Heijnsdijk EA, Katcher J, et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012;23:827-35.
21. Bill-Axelson A, Holmberg L, Garmo H, Rider JR, Taari K, Busch C, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932-42.
22. Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 2011; 117:2883-91.
23. Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA, et al. Primary treatments for clinically localised prostate cancer: A comprehensive lifetime cost-utility analysis. BJU Int 2013; 111:437-50.
24. National Center for Health Statistics. Vital statistics of the United States, Volume II: Mortality, part A. Washington DC: Government Printing Office.
25. Venzon DJ, Moolgavkar SH. A method for computing profile-likelihoodbased confidence intervals. Appl Stat 1988;37:87-94.
26. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28.
27. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375:443-53.
28. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010; 28:222-31.
29. Decision Tool for Women with BRCA Mutations; 2011[cited 2016 Jun 28]. Available from: http://brcatool.stanford.edu/.
30. Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, et al. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI Screening-MRISC, MARIBS, and Canadian studies combined. Cancer Epidemiol Biomarkers Prev 2012;21:1458-68.
31. Yen AM, Auvinen A, Schleutker J,WuYY, Fann JC, Tammela T, et al. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants. Prostate 2015;75:825-35.
32. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011;104:1656-63.
33. Shen Y, Zelen M. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol 2001;19:3490-9.
34. Cancer Intervention and Surveillance Modeling Network. Overview of CISNET modeling. Bethesda, MD: NIH; 2016 [cited 2016 Jun 28]. Available from: https://resources.cisnet.cancer.gov/registry/learn/.